Results 81 to 90 of about 2,763 (183)

Additional effect of erenumab for patients with chronic migraine treated with onabotulinumtoxin A—real-world data from a preliminary cohort study

Frontiers in Neurology
BackgroundThis preliminary retrospective cohort study investigates the potential additive prophylactic effect of erenumab, a fully human monoclonal antibody that blocks the calcitonin gene-related peptide receptor, in combination with ongoing ...
Tristan Koelsche, Petyo Nikolov, Valeria Koska, Jens Ingwersen, Robin Jansen, Ercan Arat, Sven G. Meuth, Philipp Albrecht, Philipp Albrecht, John-Ih Lee   +9 more
doaj   +1 more source

The appropriate dosing of erenumab for migraine prevention after multiple preventive treatment failures: a critical appraisal [PDF]

, 2019
BACKGROUND: Erenumab, a fully human monoclonal antibody directed against the calcitonin gene-related peptide receptor, was approved for the prevention of episodic (EM) or chronic migraine (CM) at the monthly dose of 70 mg or 140 mg.
Tiseo C., Perrotta G., Pistoia F., Sacco S., FRATTALE, ILARIA, Ornello R., Marini C.   +6 more
core   +1 more source

Early clinical experience with a monoclonal antibody against the calcitonin gene-related peptide receptor in adolescents with migraine: A case series

Proceedings of Singapore Healthcare, 2020
Management of migraine in adolescents poses a great challenge, as many of the approved pharmacological migraine preventive agents have age restrictions.
Yi Jing Zhao, King-Hee Ho, Pei Shieen Wong   +2 more
doaj   +1 more source

Migräne: Weniger Attacken und Akutmedikationen mit Erenumab

, 2018
Bisherige Studien mit Antikörpern wiesen bereits daraufhin, dass die Beeinflussung des Signalwegs des „calcitonin gene-related peptide“ (CGRP) ein wichtiges Ziel der Migränetherapie sein könnte. Mit einer Phase-3-Studie belegen Goadsby et al.

core   +1 more source

Changes in Use of Migraine Medications, Healthcare Resource Utilization, and Associated Direct Costs Over 12 Months Following Initiation of Erenumab: A US Retrospective Real-World Analysis

Pain and Therapy
Introduction Erenumab-aooe is approved for the preventive treatment of migraine in adults. Recent publications have evaluated migraine medication use during the 6 months after starting erenumab, but longer-term follow-up data are limited.
Robert Urman, Nicole Princic, Fiston Vuvu, Leah B. Patel, Sam Oh, David Chandler, Nada Hindiyeh, Mark E. Bensink   +7 more
doaj   +1 more source

Cost-utility analysis of erenumab preventive treatment for chronic migraine in China

Frontiers in Public Health
ObjectiveThis study aimed to evaluate the cost-utility of erenumab preventive treatment compared to no preventive treatment in adults with chronic migraine in China.MethodsAn individual-level microsimulation model was developed from the perspective of ...
Lijiang Wang, Menglu Zhu, Qingqing Hu, Shengying Lou, Miaolian Wu, Miaolian Wu, Miaolian Wu, Zhengqiang Hu   +7 more
doaj   +1 more source

Erenumab versus topiramate: migraine‐related disability, impact and health‐related quality of life

Background and purpose: HER-MES was the first head-to-head study of erenumab against topiramate (standard of care). This post hoc analysis of the HER-MES study evaluated the effect of erenumab versus topiramate on patient-reported outcomes at week 24.
Hentschke, Christian, Reuter, Uwe, Sieder, Christian, Gendolla, Astrid, Heinze, Axel   +4 more
core   +1 more source

A randomized, double blind, placebo-controlled pilot study to assess the efficacy of erenumab in individuals with temporomandibular disorder [PDF]

Background: Erenumab has proven efficacious in treating migraine headache. Temporomandibular disorder (TMD) is a painful disorder which has high co-occurrence rates with migraine. We hypothesized that erenumab-aooe may also be beneficial in reducing pain
Kroenke, Kurt, Eckert, George J., Zero, Domenick T., Gossweiler, Ana G., Avila, Harold C., Galvez, Lorena del Carmen   +5 more
core   +1 more source

Supplementary materials: Comparative effectiveness of erenumab versus rimegepant for migraine prevention using matching-adjusted indirect comparison

This is a peer-reviewed supplementary table for the article 'Comparative effectiveness of erenumab versus rimegepant for migraine prevention using matching-adjusted indirect comparison' published in the Journal of Comparative Effectiveness Research ...
Keith A Betts (17853358), Santosh Tiwari (7845557), Pascal Proot (17853361), Ronan Mahon (3406439), Matias Ferraris (9159495), Yan Wang (15435), Mirja Koch (5741884), Sophie Gao (17814575)   +7 more
core   +1 more source

ePoster

European Journal of Neurology, Volume 33, Issue S1, June 2026.
wiley   +1 more source